First Time Loading...

Adaptimmune Therapeutics PLC
NASDAQ:ADAP

Watchlist Manager
Adaptimmune Therapeutics PLC Logo
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Watchlist
Price: 1.04 USD -0.95% Market Closed
Updated: May 29, 2024

Adaptimmune Therapeutics PLC
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Adaptimmune Therapeutics PLC
Cash Equivalents Peer Comparison

Comparables:
CNTA
AUTL
BCYC
IMCR
GNS

Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Cash Equivalents
$140.7m
CAGR 3-Years
63%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Cash Equivalents
£442.6m
CAGR 3-Years
51%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Adaptimmune Therapeutics PLC's Cash Equivalents?
Cash Equivalents
140.7m USD

Based on the financial report for Mar 31, 2024, Adaptimmune Therapeutics PLC's Cash Equivalents amounts to 140.7m USD.

What is Adaptimmune Therapeutics PLC's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
23%

Over the last year, the Cash Equivalents growth was 17%. The average annual Cash Equivalents growth rates for Adaptimmune Therapeutics PLC have been 63% over the past three years , 23% over the past five years .